Effects of asthma treatment: the present and future

References

• Currie GP, Devereux GS, Lee DK, Ayres JG. Recent developments in asthma management. Br. Med. J.330, 585–589 (2005).
   PubMedGoogle Scholar
• Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur. Respir. J.12, 315–335 (1998).
   PubMed Web of Science ®Google Scholar
• British guideline on the management of asthma. Thorax58(Suppl. 1), i1–i94 (2003).
   PubMedGoogle Scholar
• Gibson PG, Powell H. Written action plans for asthma: an evidence-based review of the key components. Thorax59, 94–99 (2004).
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am. J. Respir. Crit. Care Med.157, S1–S53 (1998).
   PubMed Web of Science ®Google Scholar
• Olivieri D, Chetta A, Del Donno M et al. Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study. Am. J. Respir. Crit. Care Med.155, 1864–1871 (1997).
   PubMed Web of Science ®Google Scholar
• Trigg CJ, Manolitsas ND, Wang J et al. Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma. Am. J. Respir. Crit. Care Med.150, 17–22 (1994).
   PubMed Web of Science ®Google Scholar
• Wenzel SE, Szefler SJ, Leung DY, Sloan SI, Rex MD, Martin RJ. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am. J. Respir. Crit. Care Med.156, 737–743 (1997).
   PubMed Web of Science ®Google Scholar
• Booth H, Richmond I, Ward C, Gardiner PV, Harkawat R, Walters EH. Effect of high dose inhaled fluticasone propionate on airway inflammation in asthma. Am. J. Respir. Crit. Care Med.152, 45–52 (1995).
   PubMed Web of Science ®Google Scholar
• Lipworth BJ, Wilson AM. Dose-response to inhaled corticosteroids: benefits and risks. Semin. Respir. Crit. Care Med.19, 625–646 (1998).
   Web of Science ®Google Scholar
• Holt S, Suder A, Weatherall M, Cheng S, Shirtcliffe P, Beasley R. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. Br. Med. J.323, 253–256 (2001).
   PubMed Web of Science ®Google Scholar
• Currie GP, Jackson CM, Lipworth BJ. Does bronchial hyperresponsiveness in asthma matter? J. Asthma41, 247–258 (2004).
   PubMed Web of Science ®Google Scholar
• Currie GP, Fowler SJ, Lipworth BJ. Dose response of inhaled corticosteroids on bronchial hyperresponsiveness: a meta-analysis. Ann. Allergy Asthma Immunol.90, 194–198 (2003).
   PubMed Web of Science ®Google Scholar
• Lee DKC, Bates CE, Currie GP, Cowan LM, Mcfarlane LC, Lipworth BJ. Effect of high dose inhaled fluticasone propionate on the hypothalamic-pituitary-adrenal axis in asthmatics with severely impaired lung function. Chest93, 253–258 (2004).
   Google Scholar
• Brutsche MH, Brutsche IC, Munawar M et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet356, 556–561 (2000).
   PubMed Web of Science ®Google Scholar
• Ward C, Pais M, Bish R et al. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax57, 309–316 (2002).
   PubMed Web of Science ®Google Scholar
• Reddel HK, Jenkins CR, Marks GB et al. Optimal asthma control, starting with high doses of inhaled budesonide. Eur. Respir. J.16, 226–235 (2000).
   PubMed Web of Science ®Google Scholar
• Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch. Intern. Med.159, 941–955 (1999).
   PubMed Web of Science ®Google Scholar
• Pearlman DS, Berger WE, Kerwin E, Laforce C, Kundu S, Banerji D. Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma. J. Allergy Clin. Immunol.116, 1206–1212 (2005).
   PubMed Web of Science ®Google Scholar
• Lee DK, Haggart K, Currie GP, Bates CE, Lipworth BJ. Effects of hydrofluoroalkane formulations of ciclesonide 400 microg once daily vs fluticasone 250 microg twice daily on methacholine hyper-responsiveness in mild-to-moderate persistent asthma. Br. J. Clin. Pharmacol.58, 26–33 (2004).
   PubMed Web of Science ®Google Scholar
• Buhl R, Vinkler I, Magyar P et al. Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma. Pulm. Pharmacol. Ther. doi:10.1016/j.pupt.2005.10.003 (2005) (Epub ahead of print).
   Google Scholar
• Currie GP, Jackson CM, Ogston SA, Lipworth BJ. Airway-stabilizing effect of long-acting β2-agonists as add-on therapy to inhaled corticosteroids. Quarterly J. Med.96, 435–440 (2003).
   Google Scholar
• Van Der Woude HJ, Aalbers R. Long-acting β(2)-agonists: comparative pharmacology and clinical outcomes. Am. J. Respir. Med.1, 55–74 (2002).
   PubMedGoogle Scholar
• Anderson GP, Linden A, Rabe KF. Why are long-acting β-adrenoceptor agonists long-acting? Eur. Respir. J.7, 569–578 (1994).
   PubMed Web of Science ®Google Scholar
• Palmqvist M, Ibsen T, Mellen A, Lotvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am. J. Respir. Crit. Care Med.160, 244–249 (1999).
   PubMed Web of Science ®Google Scholar
• Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). Br. Med. J.320, 1368–1373 (2000).
   PubMed Web of Science ®Google Scholar
• GINA Workshop Report, Global Strategy for Asthma Management and Prevention – updated 2004. Scientific information and recommendations for asthma programs. NIH Publication No. 02–3659.
   Google Scholar
• Masoli M, Weatherall M, Holt S, Beasley R. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax60, 730–734 (2005).
   PubMed Web of Science ®Google Scholar
• Bateman ED, Boushey HA, Bousquet J et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am. J. Respir. Crit. Care Med.170, 836–844 (2004).
   PubMed Web of Science ®Google Scholar
• Calhoun WJ, Hinton KL, Kratzenberg JJ. The effect of salmeterol on markers of airway inflammation following segmental allergen challenge. Am. J. Respir. Crit. Care Med.163, 881–886 (2001).
   PubMed Web of Science ®Google Scholar
• Gardiner PV, Ward C, Booth H, Allison A, Hendrick DJ, Walters EH. Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. Am. J. Respir. Crit. Care Med.150, 1006–1011 (1994).
   PubMed Web of Science ®Google Scholar
• Roberts JA, Bradding P, Britten KM et al. The long-acting β2-agonist salmeterol xinafoate: effects on airway inflammation in asthma. Eur. Respir. J.14, 275–282 (1999).
   PubMed Web of Science ®Google Scholar
• Eickelberg O, Roth M, Lorx R et al. Ligand-independent activation of the glucocorticoid receptor by β2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J. Biol. Chem.274, 1005–1010 (1999).
   PubMed Web of Science ®Google Scholar
• Roth M, Johnson PR, Rudiger JJ et al. Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet360, 1293–1299 (2002).
   PubMed Web of Science ®Google Scholar
• Lee DK, Jackson CM, Currie GP, Cockburn WJ, Lipworth BJ. Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma. Br. J. Clin. Pharmacol.56, 494–500 (2003).
   PubMed Web of Science ®Google Scholar
• Currie GP, Bates CE, Lee DK, Jackson CM, Lipworth BJ. Effects of fluticasone plus salmeterol versus twice the dose of fluticasone in asthmatic patients. Eur. J. Clin. Pharmacol.59, 11–15 (2003).
   PubMed Web of Science ®Google Scholar
• Currie GP, Lee DK, Haggart K, Bates CE, Lipworth BJ. Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. Am. J. Respir. Crit. Care Med.167, 1232–1238 (2003).
   PubMed Web of Science ®Google Scholar
• Fish JE, Israel E, Murray JJ et al. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest120, 423–430 (2001).
   PubMed Web of Science ®Google Scholar
• Verberne AA, Frost C, Duiverman EJ, Grol MH, Kerrebijn KF. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. The Dutch Asthma Study Group. Am. J. Respir. Crit. Care Med.158, 213–219 (1998).
   PubMed Web of Science ®Google Scholar
• Green RH, Brightling CE, McKenna S et al. A randomised comparison of the effects of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and airway responsiveness. Eur. Respir. J. 0: 09031936.06.00102605v1 (2006) (Epub ahead of print).
   Google Scholar
• Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ. Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. Chest119, 1021–1026 (2001).
   PubMed Web of Science ®Google Scholar
• Lipworth BJ. Airway subsensitivity with long-acting β2-agonists. Is there cause for concern? Drug Saf.16, 295–308 (1997).
   PubMed Web of Science ®Google Scholar
• Lipworth B, Tan S, Devlin M, Aiken T, Baker R, Hendrick D. Effects of treatment with formoterol on bronchoprotection against methacholine. Am. J. Med.104, 431–438 (1998).
   PubMed Web of Science ®Google Scholar
• Lee DK, Jackson CM, Bates CE, Lipworth BJ. Cross tolerance to salbutamol occurs independently of β2 adrenoceptor genotype-16 in asthmatic patients receiving regular formoterol or salmeterol. Thorax59, 662–667 (2004).
   PubMed Web of Science ®Google Scholar
• van der Woude HJ, Winter TH, Aalbers R. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting β2 agonists. Thorax56, 529–535 (2001).
   PubMed Web of Science ®Google Scholar
• van Veen A, Weller FR, Wierenga EA, Jansen HM, Jonkers RE. A comparison of salmeterol and formoterol in attenuating airway responses to short-acting β2-agonists. Pulm. Pharmacol. Ther.16, 153–161 (2003).
   PubMed Web of Science ®Google Scholar
• Fuglsang G, Vikre-Jorgensen J, Agertoft L, Pedersen S. Effect of salmeterol treatment on nitric oxide level in exhaled air and dose-response to terbutaline in children with mild asthma. Pediatr. Pulmonol.25, 314–321 (1998).
   PubMed Web of Science ®Google Scholar
• Kalra S, Swystun VA, Bhagat R, Cockcroft DW. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. Chest109, 953–956 (1996).
   PubMed Web of Science ®Google Scholar
• Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest129, 15–26 (2006).
   PubMed Web of Science ®Google Scholar
• Mann M, Chowdhury B, Sullivan E, Nicklas R, Anthracite R, Meyer RJ. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest124, 70–74 (2003).
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG, Lotvall J. Ultra long-acting β2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin. Investig. Drugs14, 775–783 (2005).
   PubMed Web of Science ®Google Scholar
• O’Byrne P M, Bisgaard H, Godard PP et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am. J. Respir. Crit. Care Med.171, 129–136 (2005).
   PubMed Web of Science ®Google Scholar
• Currie GP, Haggart K, Lee DK et al. Effects of mediator antagonism on mannitol and adenosine monophosphate challenges. Clin. Exp. Allergy33, 783–788 (2003).
   PubMed Web of Science ®Google Scholar
• Dempsey OJ. Leukotriene receptor antagonist therapy. Postgrad. Med. J.76, 767–773 (2000).
   PubMed Web of Science ®Google Scholar
• Vaquerizo MJ, Casan P, Castillo J et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax58, 204–210 (2003).
   PubMed Web of Science ®Google Scholar
• Price DB, Hernandez D, Magyar P et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax58, 211–216 (2003).
   PubMed Web of Science ®Google Scholar
• Ducharme FM. Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence. Br. Med. J.324, 1545 (2002).
   PubMed Web of Science ®Google Scholar
• Barnes N, Thomas M, Price D, Tate H. The national montelukast survey. J. Allergy Clin. Immunol.115, 47–54 (2005).
   PubMed Web of Science ®Google Scholar
• Price D. Tolerability of montelukast. Drugs59(Suppl. 1), 35–42; discussion 43–35 (2000).
   PubMedGoogle Scholar
• Lipworth BJ, Wilson AM. Montelukast and Churg-Strauss syndrome. Thorax56, 244 (2001).
   PubMedGoogle Scholar
• Bjermer L, Bisgaard H, Bousquet J et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. Br. Med. J.327, 891 (2003).
   PubMed Web of Science ®Google Scholar
• Currie GP, Lee DK, Srivastava P. Long-acting bronchodilator or leukotriene modifier as add-on therapy to inhaled corticosteroids in persistent asthma? Chest128, 2954–2962 (2005).
   PubMed Web of Science ®Google Scholar
• Ilowite J, Webb R, Friedman B et al. Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study. Ann. Allergy Asthma Immunol.92, 641–648 (2004).
   PubMed Web of Science ®Google Scholar
• Busse WW. The role of leukotrienes in asthma and allergic rhinitis. Clin. Exp. Allergy26, 868–879 (1996).
   PubMed Web of Science ®Google Scholar
• Lipworth BJ, White PS. Allergic inflammation in the unified airway: start with the nose. Thorax55, 878–881 (2000).
   PubMed Web of Science ®Google Scholar
• Henriksen JM, Wenzel A. Effect of an intranasally administered corticosteroid (budesonide) on nasal obstruction, mouth breathing, and asthma. Am. Rev. Respir. Dis.130, 1014–1018 (1984).
   PubMed Web of Science ®Google Scholar
• Reed CE, Marcoux JP, Welsh PW. Effects of topical nasal treatment on asthma symptoms. J. Allergy Clin. Immunol.81, 1042–1047 (1988).
   PubMed Web of Science ®Google Scholar
• Wilson AM, Orr LC, Sims EJ, Dempsey OJ, Lipworth BJ. Antiasthmatic effects of mediator blockade versus topical corticosteroids in allergic rhinitis and asthma. Am. J. Respir. Crit. Care Med.162, 1297–1301 (2000).
   PubMed Web of Science ®Google Scholar
• Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ. A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma. Clin. Exp. Allergy31, 616–624 (2001).
   PubMed Web of Science ®Google Scholar
• Philip G, Malmstrom K, Hampel FC et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin. Exp. Allergy32, 1020–1028 (2002).
   PubMed Web of Science ®Google Scholar
• Philip G, Nayak AS, Berger WE et al. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr. Med. Res. Opin.20, 1549–1558 (2004).
   PubMed Web of Science ®Google Scholar
• Essayan DM. Cyclic nucleotide phosphodiesterases. J. Allergy Clin. Immunol.108, 671–680 (2001).
   PubMed Web of Science ®Google Scholar
• Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am. J. Respir. Crit. Care Med.157, 351–370 (1998).
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Theophylline: new perspectives for an old drug. Am. J. Respir. Crit. Care Med.167, 813–818 (2003).
   PubMed Web of Science ®Google Scholar
• Davies B, Brooks G, Devoy M. The efficacy and safety of salmeterol compared to theophylline: meta-analysis of nine controlled studies. Respir. Med.92, 256–263 (1998).
   PubMed Web of Science ®Google Scholar
• O'Donnell JM, Zhang HT. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). Trends Pharmacol. Sci.25, 158–163 (2004).
   PubMed Web of Science ®Google Scholar
• Renau TE. The potential of phosphodiesterase 4 inhibitors for the treatment of depression: opportunities and challenges. Curr. Opin. Investig. Drugs5, 34–39 (2004).
   PubMedGoogle Scholar
• Torphy TJ, Barnette MS, Underwood DC et al. Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm. Pharmacol. Ther.12, 131–135 (1999).
   PubMed Web of Science ®Google Scholar
• Sanz MJ, Cortijo J, Morcillo EJ. PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression. Pharmacol. Ther.106, 269–297 (2005).
   PubMed Web of Science ®Google Scholar
• Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J. Pharmacol. Exp. Ther.297, 267–279 (2001).
   PubMed Web of Science ®Google Scholar
• Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J. Pharmacol. Exp. Ther.297, 280–290 (2001).
   PubMed Web of Science ®Google Scholar
• Kumar RK, Herbert C, Thomas PS et al. Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma. J. Pharmacol. Exp. Ther.307, 349–355 (2003).
   PubMed Web of Science ®Google Scholar
• Bousquet J, Aubier M, Sastre J et al. Comparison of roflumilast, an oral anti-inflammtory, with beclomethasone dipropionate in the treatment of persistent asthma. Allergy DOI: 10.1111/j.1398–9995.2005.00931.x (2005).
   Google Scholar
• van Schalkwyk E, Strydom K, Williams Z et al. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J. Allergy Clin. Immunol.116, 292–298 (2005).
   PubMed Web of Science ®Google Scholar
• Timmer W, Leclerc V, Birraux G et al. The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-α ex vivo. J. Clin. Pharmacol.42, 297–303 (2002).
   PubMed Web of Science ®Google Scholar
• Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N. Engl. J. Med.320, 271–277 (1989).
   PubMed Web of Science ®Google Scholar
• The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur. Respir. J.22, 470–477 (2003).
   PubMed Web of Science ®Google Scholar
• Currie GP, Jackson CM, Lee DK, Lipworth BJ. Allergen sensitization and bronchial hyper-responsiveness to adenosine monophosphate in asthmatic patients. Clin. Exp. Allergy33, 1405–1408 (2003).
   PubMed Web of Science ®Google Scholar
• Currie GP, Jackson CM, Lee DK, Lipworth BJ. Determinants of airway hyperresponsiveness in mild asthma. Ann. Allergy Asthma Immunol.90, 560–563 (2003).
   PubMed Web of Science ®Google Scholar
• Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J. Allergy Clin. Immunol.115, 459–465 (2005).
   PubMed Web of Science ®Google Scholar
• Vignola AM, Humbert M, Bousquet J et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy59, 709–717 (2004).
   PubMed Web of Science ®Google Scholar
• Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy59, 701–708 (2004).
   PubMed Web of Science ®Google Scholar
• Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest125, 1378–1386 (2004).
   PubMed Web of Science ®Google Scholar
• Zuany-Amorim C, Manlius C, Dalum I et al. Induction of TNF-α autoantibody production by AutoVac TNF106: a novel therapeutic approach for the treatment of allergic diseases. Int. Arch. Allergy Immunol.133, 154–163 (2004).
   PubMed Web of Science ®Google Scholar
• Rudmann DG, Moore MW, Tepper JS et al. Modulation of allergic inflammation in mice deficient in TNF receptors. Am. J. Physiol. Lung Cell Mol. Physiol.279, L1047–L1057 (2000).
   Google Scholar
• Berry MA, Hargadon B, Shelley M et al. Evidence of a role of tumor necrosis factor α in refractory asthma. N. Engl. J. Med.354, 697–708 (2006).
   PubMed Web of Science ®Google Scholar
• Howarth PH, Babu KS, Arshad HS et al. Tumour necrosis factor (TNFα) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax60, 1012–1018 (2005).
   PubMed Web of Science ®Google Scholar
• Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N. Engl. J. Med.352, 2163–2173 (2005).
   PubMed Web of Science ®Google Scholar
• Leuppi JD, Salome CM, Jenkins CR et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am. J. Respir. Crit. Care Med.163, 406–412 (2001).
   PubMed Web of Science ®Google Scholar
• Green RH, Brightling CE, McKenna S et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet360, 1715–1721 (2002).
   PubMed Web of Science ®Google Scholar
• Jayaram L, Pizzichini MM, Cook RJ et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur. Respir. J.27, 483–494 (2006).
   PubMed Web of Science ®Google Scholar
• Currie GP, Lee DK. Exhaled nitric oxide and asthma. N. Engl. J. Med.353, 732–733; author reply 732–733 (2005).
   PubMedGoogle Scholar
• Wechsler ME, Lehman E, Lazarus SC et al. β-adrenergic receptor polymorphisms and response to salmeterol. Am. J. Respir. Crit. Care Med.173, 519–526 (2006).
   PubMed Web of Science ®Google Scholar
• Israel E, Chinchilli VM, Ford JG et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet364, 1505–1512 (2004).
   PubMed Web of Science ®Google Scholar
• Asano K, Shiomi T, Hasegawa N et al. Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma. Pharmacogenetics12, 565–570 (2002).
   PubMedGoogle Scholar
• Currie GP, Srivastava P, Dempsey OJ, Lee DK. Therapeutic modulation of allergic airways disease with leukotriene receptor antagonists. Quarterly J. Med.98, 171–182 (2005).
   Google Scholar